Loading...

Piramal Enterprises

BSE:500302
Snowflake Description

Solid track record average dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
500302
BSE
₹490B
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Piramal Enterprises Limited manufactures and sells pharmaceutical, medicinal, and chemical and botanical products in India and internationally. The last earnings update was 83 days ago. More info.


Add to Portfolio Compare Print
500302 Share Price and Events
7 Day Returns
-0.8%
BSE:500302
-0%
IN Pharmaceuticals
0.8%
IN Market
1 Year Returns
3.2%
BSE:500302
1%
IN Pharmaceuticals
-0.7%
IN Market
500302 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Piramal Enterprises (500302) -0.8% 2.1% 16.3% 3.2% 146.4% 360.6%
IN Pharmaceuticals -0% 0.8% 4.2% 1% -11.1% 36.2%
IN Market 0.8% 2.1% 5.8% -0.7% 41.2% 72.5%
1 Year Return vs Industry and Market
  • 500302 outperformed the Pharmaceuticals industry which returned 1% over the past year.
  • 500302 outperformed the Market in India which returned -0.7% over the past year.
Price Volatility
500302
Industry
5yr Volatility vs Market

500302 Value

 Is Piramal Enterprises undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Piramal Enterprises. This is due to cash flow or dividend data being unavailable. The share price is ₹2653.95.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Piramal Enterprises's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Piramal Enterprises's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BSE:500302 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in INR ₹250.67
BSE:500302 Share Price ** BSE (2019-04-18) in INR ₹2653.95
India Pharmaceuticals Industry PE Ratio Median Figure of 112 Publicly-Listed Pharmaceuticals Companies 20.2x
India Market PE Ratio Median Figure of 2,738 Publicly-Listed Companies 16.33x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Piramal Enterprises.

BSE:500302 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:500302 Share Price ÷ EPS (both in INR)

= 2653.95 ÷ 250.67

10.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Piramal Enterprises is good value based on earnings compared to the IN Pharmaceuticals industry average.
  • Piramal Enterprises is good value based on earnings compared to the India market.
Price based on expected Growth
Does Piramal Enterprises's expected growth come at a high price?
Raw Data
BSE:500302 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 10.59x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-1.6%per year
India Pharmaceuticals Industry PEG Ratio Median Figure of 32 Publicly-Listed Pharmaceuticals Companies 1.39x
India Market PEG Ratio Median Figure of 585 Publicly-Listed Companies 1.32x

*Line of best fit is calculated by linear regression .

BSE:500302 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 10.59x ÷ -1.6%

-6.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Piramal Enterprises earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Piramal Enterprises's assets?
Raw Data
BSE:500302 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in INR ₹1,299.29
BSE:500302 Share Price * BSE (2019-04-18) in INR ₹2653.95
India Pharmaceuticals Industry PB Ratio Median Figure of 133 Publicly-Listed Pharmaceuticals Companies 1.88x
India Market PB Ratio Median Figure of 3,628 Publicly-Listed Companies 1.11x
BSE:500302 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:500302 Share Price ÷ Book Value per Share (both in INR)

= 2653.95 ÷ 1,299.29

2.04x

* Primary Listing of Piramal Enterprises.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Piramal Enterprises is overvalued based on assets compared to the IN Pharmaceuticals industry average.
X
Value checks
We assess Piramal Enterprises's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Piramal Enterprises has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

500302 Future Performance

 How is Piramal Enterprises expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-1.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Piramal Enterprises expected to grow at an attractive rate?
  • Piramal Enterprises's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 7.6%.
Growth vs Market Checks
  • Piramal Enterprises's earnings are expected to decrease over the next 1-3 years, this is below the India market average.
  • Piramal Enterprises's revenue growth is expected to exceed the India market average.
Annual Growth Rates Comparison
Raw Data
BSE:500302 Future Growth Rates Data Sources
Data Point Source Value (per year)
BSE:500302 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -1.6%
BSE:500302 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 20%
India Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.6%
India Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 13.4%
India Market Earnings Growth Rate Market Cap Weighted Average 18.5%
India Market Revenue Growth Rate Market Cap Weighted Average 11.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BSE:500302 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BSE:500302 Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-03-31 195,136 29,712 2
2020-03-31 163,008 24,929 2
2019-03-31 131,980 17,319 2
BSE:500302 Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2018-12-31 127,635 49,602
2018-09-30 120,938 48,471
2018-06-30 115,200 47,499
2018-03-31 108,633 -159,666 51,215
2017-12-31 102,774 14,885
2017-09-30 97,502 14,017
2017-06-30 89,828 13,240
2017-03-31 86,902 -100,567 12,523
2016-12-31 81,244 11,803
2016-09-30 75,687 10,831
2016-06-30 71,061 10,121
2016-03-31 64,892 -69,562 9,047

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Piramal Enterprises's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Piramal Enterprises's revenue is expected to grow by 20% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BSE:500302 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Piramal Enterprises Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:500302 Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-03-31 152.30 152.30 152.30 1.00
2020-03-31 126.10 126.10 126.10 1.00
2019-03-31 78.00 78.00 78.00 1.00
BSE:500302 Past Financials Data
Date (Data in INR Millions) EPS *
2018-12-31 250.67
2018-09-30 248.86
2018-06-30 252.52
2018-03-31 281.76
2017-12-31 84.57
2017-09-30 81.22
2017-06-30 76.73
2017-03-31 72.27
2016-12-31 68.40
2016-09-30 62.77
2016-06-30 58.65
2016-03-31 52.43

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Piramal Enterprises is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Piramal Enterprises's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Piramal Enterprises has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

500302 Past Performance

  How has Piramal Enterprises performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Piramal Enterprises's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Piramal Enterprises has delivered over 20% year on year earnings growth in the past 5 years.
  • Piramal Enterprises's 1-year earnings growth exceeds its 5-year average (233.2% vs 34.7%)
  • Piramal Enterprises's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (233.2% vs 16.4%).
Earnings and Revenue History
Piramal Enterprises's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Piramal Enterprises Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:500302 Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 127,635.30 49,601.80 26,156.20
2018-09-30 120,938.00 48,471.20 25,622.90
2018-06-30 115,200.20 47,499.30 24,656.20
2018-03-31 108,632.80 51,214.90 23,592.40
2017-12-31 102,774.00 14,885.00 23,015.20
2017-09-30 97,502.00 14,016.60 22,189.40
2017-06-30 89,827.70 13,240.20 17,900.20 1,007.50
2017-03-31 86,901.50 12,523.30 21,842.20
2016-12-31 81,244.00 11,803.00 21,310.10 -313.60
2016-09-30 75,686.70 10,831.30 21,013.50 -153.00
2016-06-30 71,061.10 10,121.00 20,838.20 -140.00
2016-03-31 64,892.40 9,047.40 20,457.80
2015-12-31 63,239.80 8,657.60 24,779.60 1,424.20
2015-09-30 58,649.20 7,930.70 23,480.00 1,579.40
2015-06-30 55,641.70 1,563.70 22,649.00 2,020.70
2015-03-31 52,727.10 28,499.50 16,485.60
2014-12-31 49,650.70 24,432.00 19,730.80 2,895.40
2014-09-30 48,331.60 21,830.40 19,356.70 3,108.80
2014-06-30 47,278.50 25,415.70 19,173.30 3,276.40
2014-03-31 45,209.90 -5,014.10 18,894.90 2,956.80
2013-12-31 43,123.20 -3,904.80 15,503.30 3,079.80
2013-09-30 40,249.00 -3,182.70 14,670.90 3,134.80
2013-06-30 37,652.00 -3,780.30 14,002.50 3,024.40
2013-03-31 35,443.30 -2,272.90 13,414.00 2,867.20
2012-12-31 32,916.90 -655.50 10,200.70 2,666.20
2012-09-30 29,138.10 -1,181.00 9,141.20 3,194.80
2012-06-30 26,255.20 263.50 7,949.40 2,634.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Piramal Enterprises has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Piramal Enterprises used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
  • Piramal Enterprises has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Piramal Enterprises's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Piramal Enterprises has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

500302 Health

 How is Piramal Enterprises's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Piramal Enterprises's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Piramal Enterprises's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Piramal Enterprises's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Piramal Enterprises's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Piramal Enterprises Company Filings, last reported 3 months ago.

BSE:500302 Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 258,133.00 529,054.20 55,619.40
2018-09-30 258,133.00 529,054.20 55,619.40
2018-06-30 264,573.90 441,608.00 76,115.90
2018-03-31 264,573.90 441,608.00 76,115.90
2017-12-31 207,370.00 394,550.00 88,110.00
2017-09-30 149,428.40 400,230.50 63,475.60
2017-06-30 148,957.80 265,751.70 51,884.70
2017-03-31 148,957.80 304,509.80 50,056.60
2016-12-31 143,832.30 271,360.00 102,965.00
2016-09-30 143,832.30 271,360.00 102,965.00
2016-06-30 124,557.80 162,544.60 10,691.70
2016-03-31 129,484.70 162,787.90 10,090.60
2015-12-31 123,070.00 109,552.70 10,990.20
2015-09-30 123,070.00 109,552.70 10,990.20
2015-06-30 117,650.40 73,061.00 14,070.90
2015-03-31 117,650.40 73,061.00 14,070.90
2014-12-31 118,810.20 50,962.50 21,960.80
2014-09-30 118,810.20 50,962.50 21,960.80
2014-06-30 93,210.60 95,519.00 5,294.50
2014-03-31 93,210.60 95,519.00 5,294.50
2013-12-31 107,738.70 88,158.40 7,375.60
2013-09-30 107,738.70 88,158.40 7,375.60
2013-06-30 107,384.70 76,881.30 11,944.60
2013-03-31 107,353.60 76,881.30 11,944.60
2012-12-31 113,055.60 60,373.40 3,454.80
2012-09-30 113,055.60 60,373.40 3,454.80
2012-06-30 112,523.70 20,466.80 4,440.40
  • Piramal Enterprises's level of debt (205%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (82% vs 205% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Interest payments on debt are not well covered by earnings (EBIT is 1.6x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Piramal Enterprises's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Piramal Enterprises has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

500302 Dividends

 What is Piramal Enterprises's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.94%
Current annual income from Piramal Enterprises dividends. Estimated to be 1.45% next year.
If you bought ₹2,000 of Piramal Enterprises shares you are expected to receive ₹19 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Piramal Enterprises's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.5%).
  • Piramal Enterprises's dividend is below the markets top 25% of dividend payers in India (1.93%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BSE:500302 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
India Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 69 Stocks 0.7%
India Market Average Dividend Yield Market Cap Weighted Average of 1399 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 1.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BSE:500302 Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
2021-03-31 43.14 2.00
2020-03-31 33.63 2.00
2019-03-31 24.75 2.00
BSE:500302 Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2018-05-28 25.000 1.035
2017-08-03 21.000 0.790
2017-05-12 21.000 0.736
2016-07-11 17.500 0.977
2016-05-16 17.500 1.248
2016-03-09 17.500 1.639
2015-07-13 20.000 2.149
2015-05-08 20.000 2.075
2014-05-05 52.500 6.902
2013-07-01 17.500 3.146
2013-05-03 17.500 3.187
2012-06-14 17.500 3.343
2012-05-03 17.500 4.030
2011-10-20 6.000 1.473
2010-05-07 5.400 1.230
2009-04-24 4.200 1.197
2009-04-22 4.200 1.988

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Piramal Enterprises's earnings are paid to the shareholders as a dividend.
  • Dividends paid are thoroughly covered by earnings (10x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.6x coverage).
X
Income/ dividend checks
We assess Piramal Enterprises's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Piramal Enterprises afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Piramal Enterprises has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

500302 Management

 What is the CEO of Piramal Enterprises's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Piramal Enterprises has no CEO, or we have no data on them.
Management Team Tenure

Average tenure and age of the Piramal Enterprises management team in years:

2.4
Average Tenure
60
Average Age
  • The tenure for the Piramal Enterprises management team is about average.
Management Team

Ajay Piramal

TITLE
Chairman
COMPENSATION
₹121M
AGE
63

Swati Piramal

TITLE
Vice Chairperson
COMPENSATION
₹55M
AGE
62

Vivek Valsaraj

TITLE
Chief Financial Officer
COMPENSATION
₹175M
TENURE
1.3 yrs

Leonard D’Souza

TITLE
Compliance Officer & Company Secretary
COMPENSATION
₹9M
AGE
54

Vijay Shah

TITLE
Executive Director
COMPENSATION
₹67M
AGE
60

Nandini Piramal

TITLE
Executive Director
COMPENSATION
₹40M
AGE
38

Hitesh Dhaddha

TITLE
Chief Investor Relations Officer

Jon Sandler

TITLE
Chairman & CEO of Decision Resources Group

Anil Srivastava

TITLE
Business Head and Senior VP of APIs & Nutrition
TENURE
2.5 yrs

Suresh Raghava

TITLE
President of API Operations
TENURE
2.4 yrs
Board of Directors Tenure

Average tenure and age of the Piramal Enterprises board of directors in years:

8.7
Average Tenure
70
Average Age
  • The tenure for the Piramal Enterprises board of directors is about average.
Board of Directors

Ajay Piramal

TITLE
Chairman
COMPENSATION
₹121M
AGE
63
TENURE
12 yrs

Swati Piramal

TITLE
Vice Chairperson
COMPENSATION
₹55M
AGE
62

Vijay Shah

TITLE
Executive Director
COMPENSATION
₹67M
AGE
60
TENURE
7.3 yrs

Nandini Piramal

TITLE
Executive Director
COMPENSATION
₹40M
AGE
38
TENURE
10 yrs

Jon Sandler

TITLE
Chairman & CEO of Decision Resources Group
TENURE
7.3 yrs

Narayanan Vaghul

TITLE
Non-Executive Independent Director
COMPENSATION
₹5M
AGE
82

Deepak Satwalekar

TITLE
Non-Executive Independent Director
COMPENSATION
₹4M
AGE
70

Goverdhan Mehta

TITLE
Non-Executive Independent Director
COMPENSATION
₹3M
AGE
75
TENURE
7.3 yrs

Subramaniam Ramadorai

TITLE
Non-Executive Independent Director
COMPENSATION
₹4M
AGE
74

Keki Dadiseth

TITLE
Non-Executive Independent Director
COMPENSATION
₹4M
AGE
73
TENURE
13.3 yrs
Who owns this company?
Recent Insider Trading
  • Piramal Enterprises insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
29. Mar 19 Sell Navin Dhanuka Individual 28. Mar 19 29. Mar 19 -2,000 ₹2,750.00 ₹-5,401,914
18. Oct 18 Buy S. Sriram Individual 17. Oct 18 17. Oct 18 105 ₹2,191.05 ₹230,060
15. Oct 18 Buy S. Sriram Individual 11. Oct 18 11. Oct 18 50 ₹2,231.60 ₹111,580
11. Oct 18 Buy S. Sriram Individual 08. Oct 18 09. Oct 18 995 ₹2,137.74 ₹2,127,051
20. Sep 18 Sell Sandeep Oke Individual 19. Sep 18 19. Sep 18 -29 ₹2,888.60 ₹-83,769
07. Sep 18 Sell Vivek Valsaraj Individual 05. Sep 18 05. Sep 18 -300 ₹3,076.19 ₹-922,857
04. Sep 18 Sell Khodadad Pavri Individual 31. Aug 18 31. Aug 18 -1,000 ₹3,220.84 ₹-3,220,842
23. Aug 18 Sell Leonard D’Souza Individual 21. Aug 18 21. Aug 18 -500 ₹2,720.00 ₹-1,360,000
28. Jun 18 Sell Piramal Enterprises Limited, Executive Trust Company 25. Jun 18 26. Jun 18 -297,607 ₹2,540.60 ₹-755,062,506
12. Jun 18 Sell Piramal Enterprises Limited, Executive Trust Company 06. Jun 18 12. Jun 18 -465,000 ₹2,451.00 ₹-1,125,277,318
X
Management checks
We assess Piramal Enterprises's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Piramal Enterprises has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

500302 News

Simply Wall St News

500302 Company Info

Description

Piramal Enterprises Limited manufactures and sells pharmaceutical, medicinal, and chemical and botanical products in India and internationally. It operates in Pharmaceuticals Manufacturing and Services, Financial Services, and Healthcare Insights & Analytics segments. The company offers contract development and manufacturing solutions across the drug life cycle, including drug discovery, development, and commercial manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. It also provides inhalation anaesthetics comprising Sevoflurane, Isoflurane, and Halothane; injectable anaesthesia/pain management products that include Sublimaze, Sufenta, Rapifen, Dipidolor, and Hypnomidate; intrathecal severe spasticity/pain management products, which comprise Gablofen; and API generics, and vitamins and premixes. In addition, the company offers OTC products for skin care, pain management, oral care, respiratory, gastro-intestinal, lifestyle, and kids wellbeing under the Saridon, Lacto Calamine, I-Pill, Tetmosol, Polycrol, Naturolax, Caladryl, and Little’s brands; and PhytoMedicines products to manage lifestyle ailments, such as diabetes, arthritis, obesity, constipation, liver damage, anxiety, sexual dysfunction, cough and cold, etc. Further, it provides real estate wholesale lending, corporate finance, corporate lending, alternative asset management, housing finance, investment, and stressed asset services. Additionally, the company offers custom data and analytics, consulting, managed, and learning services; and research and data products to pharma companies, payers, and providers. Piramal Enterprises Limited has strategic alliances with CPPIB Credit Investment Inc., APG Asset Management, Bain Capital Credit, and Ivanhoé Cambridge. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is headquartered in Mumbai, India.

Details
Name: Piramal Enterprises Limited
500302
Exchange: BSE
Founded: 1947
₹489,506,900,099
184,444,658
Website: http://www.piramal.com
Address: Piramal Enterprises Limited
Piramal Ananta, Agastya Corporate Park,
109 A, 109A/1 to 109/21A, 111 and 110, 110/1 to 110/13,
Mumbai,
Maharashtra, 400070,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 500302 Equity Shares Mumbai Stock Exchange IN INR 09. Sep 1999
NSEI PEL Equity Shares National Stock Exchange of India IN INR 09. Sep 1999
Number of employees
Current staff
Staff numbers
6,843
Piramal Enterprises employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 12:46
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/01/30
Last earnings filing: 2019/01/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.